Short Interest in Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Decreases By 77.8%

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the target of a large drop in short interest during the month of February. As of February 15th, there was short interest totalling 400 shares, a drop of 77.8% from the January 31st total of 1,800 shares. Based on an average daily volume of 330,100 shares, the short-interest ratio is presently 0.0 days.

Oncotelic Therapeutics Stock Up 2.9 %

OTLC traded up $0.00 during trading on Friday, hitting $0.04. 34,173 shares of the company’s stock traded hands, compared to its average volume of 150,617. The company’s 50 day simple moving average is $0.03 and its two-hundred day simple moving average is $0.03. The company has a current ratio of 0.01, a quick ratio of 0.01 and a debt-to-equity ratio of 0.28. Oncotelic Therapeutics has a 12-month low of $0.02 and a 12-month high of $0.04. The stock has a market capitalization of $16.05 million, a price-to-earnings ratio of -3.95 and a beta of -0.29.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.